IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
TREATMENT WITH TREMFYA® RESULTED IN IMPROVEMENT IN FATIGUE AS MEASURED BY FACIT-F1

The FACIT-F endpoint in DISCOVER 2 was not adjusted for multiplicity. Therefore, statistical significance has not been established.

The FACIT-F endpoint in DISCOVER 1 was not adjusted for multiplicity. Therefore, statistical significance has not been established.

FACIT-F=Functional Assessment of Chronic Illness Therapy-Fatigue.
*Through Week 24, patients were considered to have no improvement (change=0) after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

TREMFYA® is the first and only biologic to include FACIT-F in the label for active PsA.

Reference: 1. Data on file. Janssen Biotech, Inc.